Valuation: Plus Therapeutics, Inc.

Market Cap 2.86Cr 2.51Cr 2.31Cr 2.16Cr 4.07Cr 272.23Cr 4.15Cr 28Cr 11Cr 133.63Cr 11Cr 11Cr 465.05Cr P/E 2026 *
-1.06x
P/E 2027 * -1.74x
Enterprise Value 2.86Cr 2.51Cr 2.31Cr 2.16Cr 4.07Cr 272.23Cr 4.15Cr 28Cr 11Cr 133.63Cr 11Cr 11Cr 465.05Cr EV / Sales 2026 *
4.55x
EV / Sales 2027 * 1.5x
Free-Float
98.37%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Plus Therapeutics, Inc.

1 day-5.77%
1 week-6.57%
Current month-8.92%
1 month-27.24%
3 months+11.80%
6 months-71.32%
Current year-68.92%
1 week 3.97
Extreme 3.97
4.51
1 month 3.88
Extreme 3.8784
6.03
Current year 2.9
Extreme 2.9
15.32
1 year 2.9
Extreme 2.9
23.42
3 years 2.9
Extreme 2.9
80.25
5 years 2.9
Extreme 2.9
975
10 years 2.9
Extreme 2.9
4,29,377.68
Manager TitleAgeSince
Chief Executive Officer 64 02/04/2014
Director of Finance/CFO 52 06/02/2020
Chief Tech/Sci/R&D Officer - 21/10/2025
Director TitleAgeSince
Director/Board Member 64 01/10/2002
Chairman 77 25/01/2018
Director/Board Member 66 01/01/2020
Date Insider Type Main position Quantity % Market Cap.
14/05Free

Director

7,372 0.1074%
14/05Free

Director

8,972 0.1307%
14/05Free

Director

7,372 0.1074%
Change 5-day change 1-year change 3-year change Capi.($)
-5.41%-6.57%-48.18%-92.21% 2.86Cr
+0.36%+5.10%+1.04%+6.65% 4.86TCr
-1.47%+4.57%+400.97%+594.41% 3.99TCr
+1.98%+11.14%+25.84%-6.27% 3.39TCr
+2.52%+8.31%+22.06%+64.89% 3.23TCr
+1.20%+2.26%+15.60%+32.43% 2.47TCr
+0.38%+2.88% - - 1.66TCr
+2.86%+7.07%+70.75%+132.89% 1.55TCr
+0.99%+1.26%+13.98%+18.72% 1.36TCr
-0.97%+8.33%+15.61%-28.25% 1.34TCr
Average +0.26%+7.41%+57.52%+80.36% 2.39TCr
Weighted average by Cap. +0.85%+7.73%+87.85%+128.99%

Financials

2026 *2027 *
Net sales 62.95L 55.27L 50.88L 47.41L 89.41L 60Cr 91.22L 6.12Cr 2.37Cr 29Cr 2.36Cr 2.31Cr 102.24Cr 1.91Cr 1.68Cr 1.55Cr 1.44Cr 2.72Cr 181.98Cr 2.77Cr 19Cr 7.21Cr 89Cr 7.19Cr 7.03Cr 310.88Cr
Net income -2.68Cr -2.35Cr -2.17Cr -2.02Cr -3.81Cr -254.8Cr -3.88Cr -26Cr -10Cr -125.07Cr -10Cr -9.85Cr -435.27Cr -1.85Cr -1.62Cr -1.49Cr -1.39Cr -2.62Cr -175.45Cr -2.67Cr -18Cr -6.95Cr -86Cr -6.93Cr -6.78Cr -299.73Cr
Net Debt - -
Logo Plus Therapeutics, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Employees
28
Date Price Change Volume
02/26/02 $3.970 -4.57% 1,43,941
01/26/01 $4.160 -4.81% 1,39,275
30/26/30 $4.370 +1.86% 1,64,417
29/26/29 $4.290 +2.14% 2,51,001
26/26/26 $4.200 -1.41% 2,86,155
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.160USD
Average target price
36.00USD
Spread / Average Target
+765.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSTV Stock